5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature | Zendy

Mariangela Greco | Zendy; Marianna Criscuolo | Zendy; Luana Fianchi | Zendy; Emiliano Fabiani | Zendy; Livio Pagano | Zendy; Maria Teresa Voso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

Author(s) -

Mariangela Greco,

Marianna Criscuolo,

Luana Fianchi,

Emiliano Fabiani,

Livio Pagano,

Maria Teresa Voso

Publication year - 2011

Publication title -

mediterranean journal of hematology and infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 31

ISSN - 2035-3006

DOI - 10.4084/mjhid.2011.011

Subject(s) - azacitidine , medicine , chronic myelomonocytic leukemia , myelodysplastic syndromes , peripheral blood , oncology , hypomethylating agent , leukemia , toxicity , blood count , decitabine , bone marrow , dna methylation , genetics , biology , gene expression , gene

Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research